Rossari Biotech Ltd · NSE:ROSSARI
Rossari Biotech — Q2 FY26 Earnings Presentation
33 slides from Rossari Biotech's earnings presentation, Oct 16, 2025
Slide 1: Filing cover letter to BSE and NSE
October 16, 2025 DCS-CRD Listing Compliance BSE Limited National Stock Exchange of India Limited First Floor, New Trade Wing Exchange Plaza, 5th Floor Rotunda Building, Phiroze Jeejeebhoy Towers Plot No. C/1, ‘G’ Block, Bandra- Kurla Dalal Street, Fort Mumbai 400001 Complex Bandra East Mumbai 400051
Slide 2: Q2 & H1 FY26 Results Presentation
ROSSARI BIOTECH LIMITED Q2 & H1 FY26 RESULTS PRESENTATION October 15, 2025
Slide 3: Disclaimer
Disclaimer Certain statements and opinions with respect to the anticipated future performance of Rossari Biotech Ltd (Rossari) in the presentation (“forward-looking statements”) reflect various assumptions concerning the strategies, objectives and anticipated results which may or may not prove to be
Slide 4: Q2 FY26 Results Overview, Company Overview, Annexure
1 Q2 FY26 Results Overview 2 Company Overview 3 Annexure 3
Slide 5: Q2 FY26 – Key Financial Highlights
Q2 FY26 – Key Financial Highlights Strong Quarterly Performance Highest Quarterly Revenue Highest Quarterly EBITDA Highest Quarterly PAT Revenue from Operations EBIDTA PAT (Rs. cr) (Rs. cr) (Rs. cr) 71.9 36.9 35.3 67.9 65.9 33.6 586.1 543.7 498.4 Q2 FY26 Q1 FY26 Q2 FY25 Q2 FY26 Q1 FY26 Q2 FY25 Q2 FY
Slide 6: Institutional and B2C Performance – Incubating Future Growth Verticals in Health & Hygiene
Institutional and B2C Performance – Incubating Future Growth Verticals in Health & Hygiene Revenue (Rs. cr) EBITDA (Rs. cr) Q2 FY26 Q1 FY26 Q2 FY25 75 74 70 (1) (4) (7) Q2 FY26 Q1 FY26 Q2 FY25 Shift % (Y-o-Y) 1% - Shift % (Q-o-Q) 7% - Margins (%) -5% -10% -1% • Growth in Institutional and B2C busine
Slide 7: Consolidated Performance excluding Institutional and B2C Businesses
Consolidated Performance excluding Institutional and B2C Businesses Revenue (Rs. cr) EBITDA (Rs. cr) 76 75 511 67 473 424 Q2 FY26 Q1 FY26 Q2 FY25 Q2 FY26 Q1 FY26 Q2 FY25 Shift % (Y-o-Y) 21% 13% Shift % (Q-o-Q) 8% 1% Margins (%) 15% 16% 16% • Core segments continued to deliver resilient performance d
Slide 8: Past Financial Performance Snapshot
Past Financial Performance Snapshot Revenue (Rs. cr) EBITDA (Rs. cr) PAT (Rs. cr) CAGR – 12% CAGR – 13% CAGR – 12% 250 265 131 136 2,080 223 1,656 1,831 98 107 1,483 183 FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 ROE (%) ROCE (%) Exports (Rs. cr) Net Debt to Equity (x) CAGR – 29% 57
Slide 9: Management Message
Management Message Commenting on the performance, in a joint statement, Mr. Edward Menezes, Promoter & Executive Chairman, and Mr. Sunil Chari, Promoter & Managing Director, said “We delivered healthy revenue growth of 18% YoY in Q2 FY26, led by broad-based volume expansion across our key segments.
Slide 10: Key Developments
Key Developments Update on Capacity Expansion Projects • The Company successfully commissioned an additional 20,000 MTPA capacity at its Dahej facility during the quarter; total installed capacity now at 1,52,500 MTPA • Commissioned 15,000 MTPA ethoxylation capacity at Unitop (Phase 1 of 30,000 MTPA
Slide 11: Abridged P&L Statement - Consolidated
Abridged P&L Statement - Consolidated Particulars (Rs. cr) Q2 FY26 Q2 FY25 Y-o-Y H1 FY26 H1 FY25 Y-o-Y Revenues from Operations 586.1 498.4 17.6% 1,129.8 988.0 14.4% Total Expenditure COGS 400.9 340.7 17.7% 772.2 681.6 13.3% Employee benefits expense 37.8 32.6 16.0% 75.3 61.1 23.2% Other expenses 75
Slide 12: Consolidated Balance Sheet
Consolidated Balance Sheet ASSETS EQUITY AND LIABILITIES Particulars (Rs. cr) As on 30th September 2025 As on 31st March 2025 As on 30th September As on 31st March 2025 (Unaudited) (Audited) Particulars (Rs. cr) 2025 (Unaudited) (Audited) ASSETS EQUITY NON-CURRENT ASSETS Equity Share Capital 11.1 11
Slide 13: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement Particulars (Rs. cr) H1 FY26 H1 FY25 Particulars (Rs. cr) H1 FY26 H1 FY25 (Unaudited) (Unaudited) (Unaudited) (Unaudited) A. Cash flows from operating activities B. Cash flows from investing activities Profit before tax 95.8 95.1 Net redemption from / (investment in)
Slide 14: Segment-wise Operating Performance
Segment-wise Operating Performance Quarterly Revenue Break-up (Rs. cr) Q2 FY26 Q1 FY26 Q2 FY25 586 544 498 454 424 390 101 90 84 31 30 24 HPPC TSC AHN TOTAL Shift (Y-o-Y) % 16% 21% 29% 18% Shift (Q-o-Q) % 7% 12% 3% 8% Note: 1) All figures, unless mentioned otherwise, are on a consolidated basis 2) H
Slide 15: Company Overview
COMPANY OVERVIEW 14
Slide 16: Rossari – At a Glance
Rossari – At a Glance Technocrat promoters with 45+ cumulative years of experience in the specialty chemicals industry 7* Manufacturing facilities 367,100* MTPA Capacity Installed 4* R&D Facilities 26% Revenue CAGR % (FY19-25) 20% PAT CAGR % (FY19-25) Rossari is a Specialty-Chemical manufacturer pro
Slide 17: A 25-Year Journey of Transformation
A 25-Year Journey of Transformation Delivering Value and Maintaining Synergy Along the Way Looking back in time Our Company was initially incorporated as ‘Rossari Labtech’ in March, 2003, as a partnership firm. In the same year, in December, the name of the partnership firm was changed to ‘Rossari B
Slide 18: Business Overview
Business Overview One of the leading specialty chemicals manufacturer delivering differentiated & tailor-made solutions across Home, Personal Care and Performance Chemicals (HPPC), Textile Specialty Chemicals (TSC) and Animal Health and Nutrition (AHN) businesses HPPC TSC AHN • One of the fastest-gr
Slide 19: Strengthening Market Presence
Strengthening Market Presence Strong and long-standing relationships with several clients and distributors spanning 15+ years Increasingly tapping new segments across domestic and 1 international markets 2 Building direct touch-points with several clients Growing client base of over 1,000 customers
Slide 20: Robust Manufacturing Capabilities
Robust Manufacturing Capabilities Unitop Dahej Plant Manufacturing Facility at Silvassa 75,000 MTPA • Located on 8.6 acres of land • Fungible manufacturing capabilities for powders, granules and liquids Tristar Sarigam Plant • Facility has a comprehensive range of testing & packaging capabilities •
Slide 21: Global Reach
Global Reach Market Presence RoW India 27% 73% EXPORT OPERATIONS IN 70+ COUNTRIES 20 COLLABORATE. INNOVATE. ELEVATE.
Slide 22: Growth Drivers
Growth Drivers Augmenting product Increasing wallet share 01 portfolio 04 and customer base • Enhance emphasis on green/sustainable • Cross-sell and address sourcing solutions requirements of MNC customers • Leverage R&D capabilities to develop new • Tap into new customer segments niches in product
Slide 23: Update on Key Subsidiaries
Update on Key Subsidiaries Executed synergistic acquisitions in the past complementing the ethos of Rossari’s business model Revenue (Rs. crore) CAGR – 19% • Unitop solutions sold across 25+ countries • Presence in high-potential Specialty chemical segments, such as 774 651 Agrochemicals and Oil & G
Slide 24: Key Synergies from Acquisitions
Key Synergies from Acquisitions Strategic & value-accretive acquisitions accelerate growth and drive economies of scale Augmented presence in Specialty Chemical, Personal Care and Agrochemical segments Expansion of addressable domestic and export markets and end-user applications Extension of manufa
Slide 25: Strategies: Strategic Responses to Opportunities
Strategies Strategic Responses to Opportunities Opportunity Outcomes 1. Expanding into New Business Lines • Leverage existing R&D capabilities and expertise in core • Diversified revenue streams, reduced risk from chemistries to diversify into new product segments. dependence on core segments. • Exp
Slide 26: Strategies: Sustainability and Digital Transformation
Strategies Strategic Responses to Opportunities Opportunity Outcomes 4. Enhancing Sustainability and Green Initiatives • Invest in research and development of advanced sustainable • Strengthened brand reputation as an environmentally chemical solutions. responsible company. • Explore opportunities i
Slide 27: Strategies: Strategic Responses to Threats
Strategies Strategic Responses to Threats Threats Outcomes 1. Increasing Competition • Entry of new players or intensified competition from existing rivals in the • Drive for innovation and development of differentiated products specialty chemicals market. • Competition from low-cost producers, espe
Slide 28: Focus on Green & Sustainable Chemical Solutions since Inception
Focus on Green & Sustainable Chemical Solutions since Inception Aggressively embracing sustainability in business operations to accelerate growth Specialists in producing environmentally-benign substitutes that replace legacy and harmful products Focus on green, sustainable and cost neutral products
Slide 29: Corporate Social Responsibility
Corporate Social Responsibility We at Rossari, recognize our role and responsibility to deliver superior and sustainable value to our customers, business partners, employees and communities. We have implemented various CSR initiatives with employee volunteers as well as in partnership with implement
Slide 30: Experienced Promoters and Board of Directors
Experienced Promoters and Board of Directors Founders & Promoters Independent Directors • Over 25 years of experience in the banking industry. He holds a bachelor’s degree in commerce • B. Sc. (chemistry major) from K. J. Somaiya College of Science, from H. L. Commerce College, Gujarat University. H
Slide 31: Conference Call Details
CONFERENCE CALL DETAILS Q2 FY-2026 Earnings Conference Call Time 3:30 PM IST on Friday, October 17, 2025 Pre-registration To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link: Diamond Pass Registration (choruscal
Slide 32: About Us
About Us Rossari Biotech Limited (Rossari) (BSE: 543213, NSE: ROSSARI), is a Specialty-Chemicals manufacturer providing intelligent and sustainable solutions for customers across industries. Headquartered at Mumbai, India, the Company operates strategically located manufacturing facilities at Silvas
Slide 33: Thank you
Thank y#u ‘making you more compete